Bernstein Harold, Maze Therapeutics’ President, R&D & CMO, sold 9,705 shares at $26.22 each on Sep. 4, leaving 0 shares owned. For investors, the transaction records a completed insider sale and shows that Harold no longer held Maze Therapeutics stock after the reported transaction.

Key Highlights

  • Bernstein Harold held 0 Maze Therapeutics shares after the transaction.
  • The sale occurred on 4 September 2026 under transaction code S.
  • Harold serves as Maze Therapeutics’ President, R&D & CMO.

Maze Therapeutics, Inc. (NASDAQ: MAZE) President, R&D & CMO Bernstein Harold sold 9,705 shares, reducing his reported ownership to 0 shares. The transaction was completed at $26.22 per share on 4 September 2026.

Transaction Code S Marks Open-Market Sale

The trade involved 9,705 shares at $26.22 per share. The transaction date was 4 September 2026. Maze Therapeutics’ reported ownership for Harold stood at 0 shares after the sale.